Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

Gene Therapy volume 8, pages 1618–1626 (2001)Cite this article

Abstract

Both replication-incompetent and replication-selective adenoviruses are being developed for the treatment of cancer and other diseases. Concerns have been raised about the safety of intra-vascular adenovirus administration following a patient death on a clinical trial with a replication-defective adenovirus. In addition, the feasibility of vascular delivery to distant tumors has been questioned. dl1520 (ONYX-015) is a replication-selective adenovirus that has previously shown safety and antitumoral activity following intratumoral injection. This is the first report of intra-vascular administration with a genetically engineered, replication-selective virus. A phase I dose-escalation trial was performed in patients with liver-predominant gastrointestinal carcinoma (n = 11 total; primarily colorectal). dl1520 was infused into the hepatic artery at doses of 2 × 108–2 × 1012 particles for two cycles (days 1 and 8). Subsequent cycles of dl1520 were administered in combination with intravenous 5-fluorouracil (5-FU) and leucovorin. No dose-limiting toxicity, maximally tolerated dose or treatment-emergent clinical hepatotoxicity were identified following dl1520 infusion. Mild to moderate fever, rigors and fatigue were the most common adverse events. Antibody titers increased significantly in all patients. Viral replication was detectable in patients receiving the highest two doses. An objective response was demonstrated in combination with chemotherapy in a patient who was refractory to both 5-FU and dl1520 as single agents. Therefore, hepatic artery infusion of the attenuated adenovirus dl1520 was well-tolerated at doses resulting in infection, replication and chemotherapy-associated antitumoral activity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Kozarsky KF, Wilson JM . Gene therapy: adenovirus vectors Curr Opin Genet Dev 1993 3: 499–503

    Article  CAS  PubMed  Google Scholar 

  2. Roth J, Cristiano RJ . Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997 89: 21–39

    CAS  PubMed  Google Scholar 

  3. Kirn D . Replication-selective micro-organisms: fighting cancer with targeted germ warfare J Clin Invest 2000 105: 836–838

    Article  Google Scholar 

  4. Heise C, Kirn D . Replication-selective adenviruses as oncolytic agents J Clin Invest 2000 105: 847–851

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Martuza RL et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant Science 1991 252: 854–856

    Article  CAS  PubMed  Google Scholar 

  6. Kirn DH . Replicating oncolytic viruses: an overview Expt Opin Invest Drugs 1996 5: 753–762

    Article  CAS  Google Scholar 

  7. Kirn D . Selectively-replicating viruses as therapeutic agents against cancer. In: Gene Therapy of Cancer, Vol. 1. Academic Press: San Diego 1998 pp 235–248

  8. Freytag SO et al. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy (see comments) Hum Gene Ther 1998 9: 1323–1333

    Article  CAS  PubMed  Google Scholar 

  9. Hawkins L et al. Replicating adenoviral gene therapy Proc Am Assoc Cancer Res 1999 40: 476–477

    Google Scholar 

  10. Marshall E . Clinical trials: gene therapy death prompts review of adenovirus vector Science 1999 286: 2244–2245

    Article  CAS  PubMed  Google Scholar 

  11. Beardsley T . Gene therapy setback Sci Am 2000 282: 36–37

    Article  CAS  PubMed  Google Scholar 

  12. Jenks S . Gene therapy death – everyone has to share in the guilt J Natl Cancer Inst 2000 92: 98–100

    Article  CAS  PubMed  Google Scholar 

  13. Miller H . Gene therapy on trial (letter) Science 2000 287: 591

    Article  CAS  PubMed  Google Scholar 

  14. Barker DD, Berk AJ . Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection Virology 1987 156: 107–121

    Article  CAS  PubMed  Google Scholar 

  15. Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells (see comments) Science 1996 274: 373–376

    Article  CAS  PubMed  Google Scholar 

  16. Heise C et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents (see comments) Nat Med 1997 3: 639–645

    Article  CAS  PubMed  Google Scholar 

  17. Harada J, Berk A . p53-independent and -dependent requirements for E1B-55kD in adenovirus type 5 replication J Virol 1999 73: 5333–5344

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Rothmann T et al. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells J Virol 1998 72: 9470–9478

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Goodrum FD, Ornelles DA . p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection J Virol 1998 72: 9479–9490

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Rogulski K et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy Cancer Res 2000 60: 1193–1196

    CAS  PubMed  Google Scholar 

  21. Kirn D, Hermiston T, McCormick F . ONYX-015: clinical data are encouraging Nat Med 1998 4: 1341–1342

    Article  CAS  PubMed  Google Scholar 

  22. Kirn D et al. A phase II trial of intratumoral injection with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer Proc Am Soc Clin Oncol 1998 17: 391a

    Google Scholar 

  23. Nemunaitis J et al. Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial Cancer Res 2000 60: 6359–6366

    CAS  PubMed  Google Scholar 

  24. Khuri F et al. A controlled trial of Onyx-015, an E1B gene-deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer Nat Med 2000 6: 879–885

    Article  CAS  PubMed  Google Scholar 

  25. Kirn DH et al. A phase II trial of ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Proc Am Soc Clin Oncol 1999 18: 1505 (Abstr.)

    Google Scholar 

  26. Heise C et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents (see comments) Nat Med 1997 3: 639–645

    Article  CAS  PubMed  Google Scholar 

  27. Reid A et al. A phase I/II trial of ONYX-015 administered by hepatic artery infusion to patients with colorectal carcinoma EORTC-NCI-AACR Meeting on Molecular Therapeutics of Cancer 1999

    Google Scholar 

  28. Heise C et al. Intravenous administration of ONYX-015, a selectively-replicating adenovirus, induces antitumoral efficacy Cancer Res 1999 59: 2623–2628

    CAS  PubMed  Google Scholar 

  29. Kemeny N et al. Hepatic arterial infusion of chemotherapy following resection of hepatic metastases from colorectal cancer N Engl J Med 1999 341: 2039–2048

    Article  CAS  PubMed  Google Scholar 

  30. Abbruzzese J, Evans D, Rich T . Cancer of the pancreas. In: DeVita V, Hellman S, Rosenberg S (eds). Cancer: Principles and Practice of Oncology, 5th edn Lippincott-Raven: Philadelphia 1997 pp 1054–1086

  31. Brusilow S, Maestri N . Urea cycle disorders: diagnosis, pathophysiology and therapy Adv Pediatr 1996 43: 127–170

    CAS  PubMed  Google Scholar 

  32. Roelvink P et al. Identification of a conserved reseptor-binding site on the fiber proteins of CAR-recognizing adenoviridae Science 1999 286: 1568–1571

    Article  CAS  PubMed  Google Scholar 

  33. Yang Y, Trinchieri G, Wilson JM . Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung (see comments) Nat Med 1995 1: 890–893

    Article  CAS  PubMed  Google Scholar 

  34. Mastrangeli A et al. Sero-switch adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype Hum Gene Ther 1996 7: 79–87

    Article  CAS  PubMed  Google Scholar 

  35. Heise C et al. An adenovirus E1A mutant that demonstrates potent and selective antitumoral efficacy Nat Med 2000 6: 1134–1139

    Article  CAS  PubMed  Google Scholar 

  36. Heise C, Lemmon M, Kirn D . Replication-selective adenovirus plus cisplatin chemotherapy efficacy is dependent on sequencing but independent of p53 status Clin Cancer Res 2000 6: 4908–4914

    CAS  PubMed  Google Scholar 

  37. Nemunaitis J, Cunningham C, Randlev B, Kirn D . Intravenous infusion of a replication-selective adenovirus (Onyx-015) in cancer patients: safety feasibility and biological activity Gene Therapy 2001 8: 746–759

    Article  CAS  PubMed  Google Scholar 

  38. Barker DD, Berk AJ . Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection Virology 1987 156: 107–121

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank the following individuals for their assistance: Margaret Uprichard, Sherry Toney, Amy Waterhouse, Patrick Trown, Deborah Hahn, Ellen Morgan, Phil Custodio.

Author information

Authors and Affiliations

  1. Palo Alto Veterans Administration Hospital and Stanford University Medical Center, Palo Alto, CA, USA

    T Reid & D Sze

  2. Mayo Clinic, Rochester, MN, USA

    E Galanis, J Andrews & J Rubin

  3. MD Anderson Cancer Center, Houston, TX, USA

    J Abbruzzese

  4. Onyx Pharmaceuticals, Richmond, CA, USA

    L Romel & M Hatfield

  5. Imperial Cancer Research Fund, Imperial College School of Medicine, London, UK

    D Kirn

Authors
  1. T Reid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Galanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Abbruzzese
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Sze
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Andrews
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Romel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Hatfield
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Rubin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D Kirn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Kirn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reid, T., Galanis, E., Abbruzzese, J. et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 8, 1618–1626 (2001). https://doi.org/10.1038/sj.gt.3301512

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301512

Keywords

This article is cited by

Search

Advanced search

Quick links